Anti-PD-L1 antibodies
US-10517949-B2 · Dec 31, 2019 · US
Cross-Sectional Technologies
Cross-Sectional Technologies · Cooperative Patent Classification (CPC)
General tagging of emerging or interdisciplinary technologies.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | Y02A50/412 |
| Official title | — |
| Display label | Cross-Sectional Technologies (mapped technology topic) |
| Total patents | 147 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity appears to be declining based on the most recent years.
| Year | Patents |
|---|---|
| 2018 | 24 |
| 2019 | 73 |
| 2020 | 48 |
| 2021 | 2 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Anti-CD79B antibodies and immunoconjugates and methods of use
US-10494432-B2 · Dec 3, 2019 · US
Carbon nanotube compositions and methods of use thereof
US-10485856-B2 · Nov 26, 2019 · US
Method and compositions
US-10485865-B2 · Nov 26, 2019 · US
Primary mesenchymal stem cells as a vaccine platform
US-10472647-B2 · Nov 12, 2019 · US
Conjugates of cell binding molecules with cytotoxic agents
US-2019330149-A1 · Oct 31, 2019 · US
Monoclonal antibodies to programmed death 1 (PD-1)
US-10441655-B2 · Oct 15, 2019 · US
Conjugates of cell binding molecules with cytotoxic agents
US-10399941-B2 · Sep 3, 2019 · US
Lipidated immune response modifier compound compositions, formulations, and methods
US-10383938-B2 · Aug 20, 2019 · US
Combination immunotherapy compositions against cancer and methods
US-10383924-B2 · Aug 20, 2019 · US
Contructs for enhancing immune responses
US-10328146-B2 · Jun 25, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10323093-B2 · Jun 18, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10323092-B2 · Jun 18, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10316090-B2 · Jun 11, 2019 · US
Vaccination in newborns and infants
US-2019167782-A1 · Jun 6, 2019 · US
Combination of vaccination and OX40 agonists
US-10307472-B2 · Jun 4, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10308714-B2 · Jun 4, 2019 · US
Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
US-10300128-B2 · May 28, 2019 · US
Methods for achieving therapeutically effective doses of anti-CD47 agents
US-10301387-B2 · May 28, 2019 · US
VACCINATION WITH mRNA-CODED ANTIGENS
US-2019151438-A1 · May 23, 2019 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC Y02A50/412?
- CPC Y02A50/412 is the Cooperative Patent Classification code for “Cross-Sectional Technologies.”
- How many patents are filed under CPC Y02A50/412 (Cross-Sectional Technologies)?
- Our database includes 147 publications tagged with this CPC code.
- Is patent activity under CPC Y02A50/412 growing?
- Publication counts under this code: 48 in 2020 vs 2 in 2021 (latest complete years).